Strategic Cooperation between GeneQuantum Healthcare and Biocytogen on Development of Antitumor Bioconjugates
The list of “Unicorn-to-Be” companies in Suzhou was released recently. Genequantum Healthcare (Suzhou) Co., Ltd. was honored as one of them.
Suzhou announced the "Suzhou Unicorn Enterprise Cultivation Plan (2018-2022)" in 2018, aiming to encourage local enterprises for innovative development. The companies on the list are mainly involved in industries such as big data, automatic driving, information technology, e-commerce, speech recognition, high-end equipment manufacturing, new energy, and new materials.
Since established, Genequantum has focused on the development of innovative bioconjugates, such as ADC (Antibody-drug-conjugate) drugs. Through interdisciplinary and differentiated innovation, Genequantum independently developed the international leading ligase catalytic conjugation technology and the intelligent continuous ligase-dependent conjugation (iLDC) platform. The world’s first site-specific transpeptidase-catalyzed ADC drug, GQ1001, was developed on the iLDC platform. GQ1001 has entered global multi-center clinical trial in US, Australia and China, and is sponsored by “national major new drug creation” funding.
Standing out from the competition to be named as "Unicorn-to Be", Genequantum is fully recognized and supported by SuZhou government for its innovation capabilities. Genequantum will speed up research and development and utilize the iLDC platform to lead in the field of innovative bioconjugate which is represented by ADC drugs, to provide efficient, safe and accessible innovative drugs to global cancer patients.
About GeneQuantum Healthcare
GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech biopharmaceutical company dedicated to the development of innovative biotherapeutics. The company is focused on the development of a new generation of bioconjugate therapeutics to meet the unmet medical needs of cancer patients globally. For more information, visit www.genequantum.com.
This press contains statements related to our future business, future events or developments, and related statements may constitute forward-looking statements. The statement is based on current expectations and contains a statement description of known or unknown risks, including but not limited to the uncertainties inherent in research and development, follow-up clinical data and analysis; factors that may cause delays, transfers or changes; regulatory agencies decide whether and when to approve any drug applications submitted for such product candidates; and factors that may cause actual results to seriously deviate from current expectations, etc. No forward-looking statement can be guaranteed. Except as required by applicable laws, Genequantum assumes no obligation to update or revise any forward-looking information or statements.